Understanding ABECMA® (idecabtagene vicleucel)

Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma (RRMM) after 2 or more prior lines of therapy. Immunotherapy is treatment that enhances the body’s natural defenses. Chimeric antigen receptor (CAR) T-cell therapy with Abecma takes the patient’s own T cells and engineers them to identify the B-cell maturation antigen (BCMA) receptor on the surface of myeloma cells, bind to this receptor, and destroy the myeloma cells. Abecma is a personalized immunotherapy that is manufactured for each individual patient and is delivered as a one-time infusion.